FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jacques Barbet

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Disorders

Concepts & Ideas

Tissue Distribution

Anatomy

Tumor Cell Line

Co-author Network

Publications

TOP 3
Thomas Carlier; Thomas Eugène; Ludovic Ferrer; Etienne Garin; Catherine Ansquer; Jacques Barbet; Caroline Bodet-Milin; Caroline Rousseau; Frédéric Schoenahl; Françoise Kraeber-Bodéré
Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.
Pierre-Yves Salaun; Robert M Sharkey; David Taieb; Jean-Philippe Vuillez; Eric Mirallié; Aurore Oudoux; Caroline Rousseau; Catherine Ansquer; Jacques Barbet; Stéphane Bardet; Françoise Borson-Chazot; Claire Bournaud; Loïc Campion; Bertrand Cariou; Chien-Hsing Chang; Jean-François Chatal; Alain Faivre-Chauvet; David M Goldenberg; Françoise Kraeber-Bodéré
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Françoise Kraeber-Bodéré; Eric Mirallié; Pierre-Yves Salaun; Catherine Ansquer; Jacques Barbet; Delphine Drui; Alain Faivre-Chauvet; David M Goldenberg; Jean-François Chatal
Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jacques Barbet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Thomas Carlier; Thomas Eugène; Ludovic Ferrer; Etienne Garin; Catherine Ansquer; Jacques Barbet; Caroline Bodet-Milin; Caroline Rousseau; Frédéric Schoenahl; Françoise Kraeber-Bodéré
Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.
EJNMMI research 2013;3(1):11.
2012: Pierre-Yves Salaun; Robert M Sharkey; David Taieb; Jean-Philippe Vuillez; Eric Mirallié; Aurore Oudoux; Caroline Rousseau; Catherine Ansquer; Jacques Barbet; Stéphane Bardet; Françoise Borson-Chazot; Claire Bournaud; Loïc Campion; Bertrand Cariou; Chien-Hsing Chang; Jean-François Chatal; Alain Faivre-Chauvet; David M Goldenberg; Françoise Kraeber-Bodéré
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(8):1185-92.
2012: Françoise Kraeber-Bodéré; Eric Mirallié; Pierre-Yves Salaun; Catherine Ansquer; Jacques Barbet; Delphine Drui; Alain Faivre-Chauvet; David M Goldenberg; Jean-François Chatal
Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(3):601-6.
2012: Caroline Rousseau; Stéphane Supiot; John Wijdenes; Jacques Barbet; Manuel Bardiès; Pierre Baumgartner; François Davodeau; Alain Faivre-Chauvet; Ludovic Ferrer; Thierry Guillaume; Jean-Luc Harousseau; Françoise Kraeber-Bodéré; Marie Lacombe; Philippe Moreau; Michel Cherel
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(3):679-88.
2012: Jacques Barbet; Manuel Bardiès; Mickael Bourgeois; Jean-François Chatal; Michel Chérel; François Davodeau; Alain Faivre-Chauvet; Jean-François Gestin; Françoise Kraeber-Bodéré
Radiolabeled antibodies for cancer imaging and therapy.
Methods in molecular biology (Clifton, N.J.) 2012;907():681-97.
2012: Nadège Anizan; Jacques Barbet; Thomas Carlier; Cecilia Hindorf; Manuel Bardiès
dAcquisition setting optimization and quantitative imaging for 124I studies with the Inveon microPET-CT system.
EJNMMI research 2012;2():7.
2011: Eric Frampas; David M Goldenberg; Catherine Maurel; Thibault Mauxion; Patricia Remaud-Le Saëc; Manuel Bardiès; François Davodeau; Alain Faivre-Chauvet; Jacques Barbet
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide.
European journal of nuclear medicine and molecular imaging 2011;38(12):2153-64.
2011: Faisal Alshoukr; Jacques Barbet; Luc Brans; Abdelhak Jallane; Sandra Mendes; Aurélie Prignon; Jean-Noël Talbot; Dirk Tourwé; Anne Gruaz-Guyon
Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Bioconjugate chemistry 2011;22(7):1374-85.
2011: Eric Frampas; Catherine Maurel; Philippe Thedrez; Patricia Remaud-Le Saëc; Alain Faivre-Chauvet; Jacques Barbet
The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody.
Nuclear medicine communications 2011;32(2):147-54.
2011: Nidia Alvarez-Rueda; Jacques Aubry; Jacques Barbet; Gwenola Bougras; Tanguy Chaumette; Béatrice Clemenceau; Denis Cochonneau; Ariane Desselle; Stéphanie Leprieur; Jean-Marie Mussini; François Paris; Julie Saba; Stéphane Supiot; Stéphane Birklé
A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
PloS one 2011;6(9):e25220.
2011: Eliot P Botosoa; Mike Maillasson; Marie Mougin-Degraef; Patricia Remaud-Le Saëc; Jean-François Gestin; Yannick Jacques; Jacques Barbet; Alain Faivre-Chauvet
Antibody-Hapten Recognition at the Surface of Functionalized Liposomes Studied by SPR: Steric Hindrance of Pegylated Phospholipids in Stealth Liposomes Prepared for Targeted Radionuclide Delivery.
Journal of drug delivery 2011;2011():368535.
2010: Françoise Kraeber-Bodéré; Caroline Bodet-Milin; Colin Niaudet; Catherine Saï-Maurel; Anne Moreau; Alain Faivre-Chauvet; Patrick Thomare; Gerard Deleris; Karine Estieu-Gionnet; Andréas Bikfalvi; Jacques Barbet; François Paris
Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(4):624-31.
2010: Françoise Kraeber-Bodéré; Pierre-Yves Salaun; Aurore Oudoux; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
Cancer 2010;116(4 Suppl):1118-25.
2010: Pierre-Yves Salaun; Caroline Bodet-Milin; Eric Frampas; Aurore Oudoux; Catherine Saï-Maurel; Alain Faivre-Chauvet; Jacques Barbet; François Paris; Françoise Kraeber-Bodéré
Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
Cancer 2010;116(4 Suppl):1053-8.
2009: Jacques Barbet; Jean-François Chatal; Françoise Kraeber-Bodéré
[Radiolabeled antibodies for cancer treatment].
Médecine sciences : M/S 2009;25(12):1039-45.
2009: Jean-François Chatal; François Davodeau; Michel Cherel; Jacques Barbet
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors.
Journal of cancer research and therapeutics 2009;5 Suppl 1():S36-40.
2009: Françoise Kraeber-Bodéré; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.
Current oncology (Toronto, Ont.) 2009;16(5):3-8.
2008: Jacques Barbet; Françoise Kraeber-Bodéré; Jean-François Chatal
What can be expected from nuclear medicine tomorrow?
Cancer biotherapy & radiopharmaceuticals 2008;23(4):483-504.
2008: Charles Thomas; Josiane Charrier; Catherine Massart; Michel Cherel; Bernard Fertil; Jacques Barbet; Nicolas Foray
Low-dose hyper-radiosensitivity of progressive and regressive cells isolated from a rat colon tumour: impact of DNA repair.
International journal of radiation biology 2008;84(7):533-48.
2008: Jean-François Chatal; Françoise Kraeber-Bodéré; Jacques Barbet
Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure?
European journal of nuclear medicine and molecular imaging 2008;35(7):1236-9.
2007: Aurore Oudoux; Pierre-Yves Salaun; Claire Bournaud; Loïc Campion; Catherine Ansquer; Caroline Rousseau; Stéphane Bardet; Françoise Borson-Chazot; Jean-Philippe Vuillez; Arnaud Murat; Eric Mirallié; Jacques Barbet; David M Goldenberg; Jean-François Chatal; Françoise Kraeber-Bodéré
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
The Journal of clinical endocrinology and metabolism 2007;92(12):4590-7.
2007: Marie Mougin-Degraef; C Bourdeau; Emmanuelle Jestin; Catherine Saï-Maurel; M Bourgeois; P Remaud-Le Saëc; Philippe Thédrez; Jean-François Gestin; Jacques Barbet; Alain Faivre-Chauvet
Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.
International journal of pharmaceutics 2007;344(1-2):110-7.
2007: Chantal Curtet; Thomas Carlier; Eric Mirallié; Caroline Bodet-Milin; Caroline Rousseau; Jacques Barbet; Françoise Kraeber-Bodéré
Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.
European journal of nuclear medicine and molecular imaging 2007;34(10):1556-62.
2007: Mickaël Bourgeois; Marie Mougin-Degraef; Françoise Leost; Michel Cherel; Jean-François Gestin; Didier Le Bars; Jacques Barbet; Alain Faivre-Chauvet
Purification of [18F]-fluoro-L-thymidine ([18F]-FLT) for positron emission tomography imaging.
Journal of pharmaceutical and biomedical analysis 2007;45(1):154-7.
2007: Nidia Alvarez-Rueda; Stéphanie Leprieur; Béatrice Clémenceau; Stéphane Supiot; Véronique Sébille-Rivain; Alain Faivre-Chauvet; François Davodeau; François Paris; Jacques Barbet; Jacques Aubry; Stéphane Birklé
Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5613s-5620s.
2007: Alain Sézeur; François Châtelet; Ch Cywiner; Claire de Labriolle Vaylet; C Chastang; Cl Billotey; Michel Malafosse; Denis Gallot; Pierre Olivier Betton; Françoise Montravers; S Carvajal-Gonzalez; Serge Askienazy; Jean-Noël Talbot; Jean-Didier Rain; G Milhaud; G Saumon; Jacques Barbet; Anne Gruaz-Guyon
Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5592s-5597s.
2007: Nicolas Chouin; Abdalkader Bitar; Albert Lisbona; Michel Chérel; François Davodeau; Jacques Barbet; Manuel Bardiès
Implementation of a microdosimetric model for radioimmunotherapeutic alpha emitters.
Cancer biotherapy & radiopharmaceuticals 2007;22(3):387-92.
2007: Emmanuelle Jestin; Marie Mougin-Degraef; Alain Faivre-Chauvet; P Remaud-Le Saëc; F Hindre; J P Benoit; Jean-François Chatal; Jacques Barbet; Jean-François Gestin
Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapy.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2007;51(1):51-60.
2007: Nidia Alvarez-Rueda; Ghislaine Behar; Virginie Ferré; Martine Pugnière; Françoise Roquet; Louis Gastinel; Catherine Jacquot; Jacques Aubry; Daniel Baty; Jacques Barbet; Stéphane Birklé
Generation of llama single-domain antibodies against methotrexate, a prototypical hapten.
Molecular immunology 2007;44(7):1680-90.
2007: Abdalkader Bitar; Albert Lisbona; Philippe Thedrez; C Sai Maurel; D Le Forestier; Jacques Barbet; M Bardies
A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP).
Physics in medicine and biology 2007;52(4):1013-25.
2007: Stéphanie Bonnaud; Colin Niaudet; Géraldine Pottier; Marie-Hélène Gaugler; Julie Millour; Jacques Barbet; Laure Sabatier; François Paris
Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death.
Cancer research 2007;67(4):1803-11.
2006: Jean-François Chatal; Loïc Campion; Françoise Kraeber-Bodéré; Stéphane Bardet; Jean-Philippe Vuillez; Bernard Charbonnel; Vincent Rohmer; Chien-Hsing Chang; Robert M Sharkey; David M Goldenberg; Jacques Barbet
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1705-11.
2006: Sophie Chiavassa; Isabelle Aubineau-Lanièce; Abdalkader Bitar; Albert Lisbona; Jacques Barbet; Didier Franck; Jean-Rene Jourdain; Manuel Bardiès
Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code.
Physics in medicine and biology 2006;51(3):601-16.
2006: Françoise Kraeber-Bodéré; Caroline Rousseau; Caroline Bodet-Milin; Ludovic Ferrer; Alain Faivre-Chauvet; Loïc Campion; Jean-Philippe Vuillez; Anne Devillers; Chien-Hsing Chang; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(2):247-55.
2006: Marie Mougin-Degraef; Emmanuelle Jestin; Damien Bruel; Patricia Remaud-Le Saëc; Laurence Morandeau; Alain Faivre-Chauvet; Jacques Barbet
High-activity radio-iodine labeling of conventional and stealth liposomes.
Journal of liposome research 2006;16(1):91-102.
2005: Jacques Barbet; Loïc Campion; Françoise Kraeber-Bodéré; Jean-François Chatal
Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
The Journal of clinical endocrinology and metabolism 2005;90(11):6077-84.
2005: Stéphane Supiot; Sébastien Gouard; Josiane Charrier; Christos Apostolidis; Jean-François Chatal; Jacques Barbet; François Davodeau; Michel Cherel
Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7047s-7052s.
2005: Karine Bernardeau; Sébastien Gouard; Gaëlle David; Anne-Lise Ruellan; Anne Devys; Jacques Barbet; Marc Bonneville; Michel Chérel; François Davodeau
Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
European journal of immunology 2005;35(10):2864-75.
2005: Eric Mirallié; Catherine Saï-Maurel; Alain Faivre-Chauvet; Nicolas Regenet; Chien-Hsing Chang; David M Goldenberg; Jean-François Chatal; Jacques Barbet; Philippe Thedrez
Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
European journal of nuclear medicine and molecular imaging 2005;32(8):901-9.
2005: Olivier Raguin; Marie-Claude Fournié-Zaluski; Anthony Romieu; André Pèlegrin; François Chatelet; Didier Pélaprat; Jacques Barbet; Bernard P Roques; Anne Gruaz-Guyon
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
Angewandte Chemie (International ed. in English) 2005;44(26):4058-61.
2005: Eric Mirallié; Jean-Philippe Vuillez; Stéphane Bardet; Eric Frampas; B Dupas; Ludovic Ferrer; Alain Faivre-Chauvet; Arnaud Murat; Bernard Charbonnel; Jacques Barbet; David M Goldenberg; Jean-François Chatal; Françoise Kraeber-Bodéré
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer.
The Journal of clinical endocrinology and metabolism 2005;90(2):779-88.
2005: Anne Gruaz-Guyon; Olivier Raguin; Jacques Barbet
Recent advances in pretargeted radioimmunotherapy.
Current medicinal chemistry 2005;12(3):319-38.
2005: Laurence Morandeau; E Benoist; Anthony Loussouarn; Ali Ouadi; P Lesaec; M Mougin; Alain Faivre-Chauvet; J Le Boterff; Jean-François Chatal; Jacques Barbet; Jean-François Gestin
Synthesis of new bivalent peptides for applications in the Affinity Enhancement System.
Bioconjugate chemistry 2005;16(1):184-93.
2003: Françoise Kraeber-Bodéré; Alain Faivre-Chauvet; Ludovic Ferrer; Jean-Philippe Vuillez; Pierre-Yves Brard; Caroline Rousseau; Isabelle Resche; Anne Devillers; Sophie Laffont; Manuel Bardiès; Ken Chang; Robert M Sharkey; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3973S-81S.
2002: Olivier Raguin; Anne Gruaz-Guyon; Jacques Barbet
Equilibrium expert: an add-in to Microsoft Excel for multiple binding equilibrium simulations and parameter estimations.
Analytical biochemistry 2002;310(1):1-14.
2002: Agnès Groulet; Mylène Dorvillius; André Pèlegrin; Jacques Barbet; Daniel Baty
Pharmacokinetic and tumor-seeking properties of recombinant and nonrecombinant anti-carcinoembryonic antigen antibody fragments.
International journal of cancer. Journal international du cancer 2002;100(3):367-74.
2002: Marc Hillairet de Boisferon; Olivier Raguin; Cynthia Thiercelin; Monique Dussaillant; William Rostène; Jacques Barbet; André Pélegrin; Anne Gruaz-Guyon
Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.
Bioconjugate chemistry 2002;13(3):654-62.
2002: Françoise Kraeber-Bodéré; Catherine Saï-Maurel; Loïc Campion; Alain Faivre-Chauvet; Eric Mirallié; Michel Chérel; Stéphane Supiot; Jacques Barbet; Jean-François Chatal; Philippe Thédrez
Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
Molecular cancer therapeutics 2002;1(4):267-74.
2001: Anne Gruaz-Guyon; E Janevik-Ivanovska; Olivier Raguin; Claire de Labriolle Vaylet; Jacques Barbet
Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 2001;45(2):201-6.
2001: Jean-François Gestin; Anthony Loussouarn; Manuel Bardiès; Emmanuel Gautherot; Anne Gruaz-Guyon; Catherine Saï-Maurel; Jacques Barbet; Chantal Curtet; Jean-François Chatal; Alain Faivre-Chauvet
Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(1):146-53.
2000: André Pèlegrin; Françoise Xavier; Jacques Barbet; J Bartholeyns; Daniel Baty; Franz Buchegger; Jean-François Chatal; F Dufief; D Gurreau; Anne Gruaz-Guyon; D Lamotte; Lee Leserman; Jean-Pierre Mach; Bruno Robert; J C Saccavini; J L Teillaud; Isabelle Teulon
[Immunotargeting of tumors: state of the art and prospects in 2000].
Bulletin du cancer 2000;87(11):777-91.
2000: Marc Hillairet de Boisferon; Olivier Raguin; M Dussaillant; William Rostène; Jacques Barbet; Anne Gruaz-Guyon
Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens.
Bioconjugate chemistry 2000;11(4):452-60.
2000: M N Hosono; Masako N Hosono; A K Mishra; Alain Faivre-Chauvet; Emmanuel Gautherot; Jacques Barbet; Furn F Knapp; Jean-François Chatal
Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer.
Annals of nuclear medicine 2000;14(3):173-9.
2000: Emmanuel Gautherot; E Rouvier; Laurent Daniel; E Loucif; J Bouhou; C Manetti; M Martin; JM Le Doussal; Jacques Barbet
Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(3):480-7.
2000: Claire de Labriolle Vaylet; Pierre Cattan; Emile Sarfati; M Wioland; Cl Billotey; C Brochériou; E Rouvier; A de Roquancourt; William Rostène; Serge Askienazy; Jacques Barbet; G Milhaud; Anne Gruaz-Guyon
Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):363-71.
1999: Jean-Philippe Vuillez; Françoise Kraeber-Bodéré; denis moro-sibilot; Manuel Bardiès; J Y Douillard; Emmanuel Gautherot; E Rouvier; Jacques Barbet; F Garban; P Moreau; Jean-François Chatal
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3259s-3267s.
1999: Françoise Kraeber-Bodéré; Stéphane Bardet; Cornelis A Hoefnagel; M R Vieira; Jean-Philippe Vuillez; Arnaud Murat; T C Ferreira; Manuel Bardiès; Ludovic Ferrer; Isabelle Resche; Emmanuel Gautherot; E Rouvier; Jacques Barbet; Jean-François Chatal
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3190s-3198s.
1999: Françoise Kraeber-Bodéré; Alain Faivre-Chauvet; Catherine Saï-Maurel; Loïc Campion; Maryse Fiche; Emmanuel Gautherot; J Le Boterff; Jacques Barbet; Jean-François Chatal; Philippe Thédrez
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3183s-3189s.
1999: Emmanuel Gautherot; Françoise Kraeber-Bodéré; Laurent Daniel; Maryse Fiche; E Rouvier; Catherine Saï-Maurel; Philippe Thedrez; Jean-François Chatal; Jacques Barbet
Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3177s-3182s.
1999: M Hosono; Masako N Hosono; Françoise Kraeber-Bodéré; Anne Devys; Philippe Thédrez; Alain Faivre-Chauvet; Emmanuel Gautherot; Jacques Barbet; Jean-François Chatal
Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(7):1216-21.
1999: Jacques Barbet; Françoise Kraeber-Bodéré; Jean-Philippe Vuillez; Emmanuel Gautherot; E Rouvier; Jean-François Chatal
Pretargeting with the affinity enhancement system for radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 1999;14(3):153-66.
1999: Françoise Kraeber-Bodéré; A Faibre-Chauvet; Catherine Saï-Maurel; Emmanuel Gautherot; Maryse Fiche; Loïc Campion; J Le Boterff; Jacques Barbet; Jean-François Chatal; Philippe Thédrez
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(1):198-204.
1998: Karine Serre; Patrick Machy; J C Grivel; G Jolly; N Brun; Jacques Barbet; Lee Leserman
Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(11):6059-67.
1998: Emmanuel Gautherot; JM Le Doussal; J Bouhou; C Manetti; M Martin; E Rouvier; Jacques Barbet
Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(11):1937-43.
1998: Masako N Hosono; M N Hosono; Françoise Kraeber-Bodéré; Anne Devys; Philippe Thédrez; Maryse Fiche; Emmanuel Gautherot; Jacques Barbet; Jean-François Chatal
Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(9):1608-13.
1998: Jacques Barbet; P Peltier; Stéphane Bardet; Jean-Philippe Vuillez; I Bachelot; S Denet; P Olivier; F Leccia; B Corcuff; D Huglo; C Proye; E Rouvier; P Meyer; Jean-François Chatal
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(7):1172-8.
1997: Emmanuel Gautherot; J Bouhou; JM Le Doussal; C Manetti; M Martin; E Rouvier; Jacques Barbet
Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
Cancer 1997;80(12 Suppl):2618-23.
1997: E Janevik-Ivanovska; Emmanuel Gautherot; Marc Hillairet de Boisferon; M Cohen; G Milhaud; A Tartar; William Rostene; Jacques Barbet; Anne Gruaz-Guyon
Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy.
Bioconjugate chemistry 1997;8(4):526-33.
1997: C Manetti; E Rouvier; Emmanuel Gautherot; E Loucif; Jacques Barbet; JM Le Doussal
Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
International journal of cancer. Journal international du cancer 1997;71(6):1000-9.
1997: Jean-Philippe Vuillez; denis moro-sibilot; Pierre-Yves Brichon; E Rouvier; E Brambilla; Jacques Barbet; P Peltier; P Meyer; R Sarrazin; C Brambilla
Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(4):507-11.
1997: E Rouvier; Emmanuel Gautherot; P Meyer; Jacques Barbet
Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives.
Hormone research 1997;47(4-6):163-7.
1996: Manuel Bardiès; Stéphane Bardet; Alain Faivre-Chauvet; P Peltier; J Y Douillard; M Mahé; Maryse Fiche; A Lisbona; F Giacalone; P Meyer; Emmanuel Gautherot; E Rouvier; Jacques Barbet; Jean-François Chatal
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(11):1853-9.
1996: A Devys; P Thedrez; Emmanuel Gautherot; Alain Faivre-Chauvet; Catherine Saï-Maurel; E Rouvier; J L Auget; Jacques Barbet; Jean-François Chatal
Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
International journal of cancer. Journal international du cancer 1996;67(6):883-91.
1995: C Manetti; JM Le Doussal; E Rouvier; A Gruaz-Guyon; Jacques Barbet
Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.
International journal of cancer. Journal international du cancer 1995;63(2):250-6.
1995: V Boden; C Colin; Jacques Barbet; JM Le Doussal; Mookambeswaran A Vijayalakshmi
Preliminary study of the metal binding site of an anti-DTPA-indium antibody by equilibrium binding immunoassays and immobilized metal ion affinity chromatography.
Bioconjugate chemistry 1995;6(4):373-9.
1995: Jean-François Chatal; Alain Faivre-Chauvet; M Bardies; P Peltier; Emmanuel Gautherot; Jacques Barbet
Bifunctional antibodies for radioimmunotherapy.
Hybridoma 1995;14(2):125-8.
1995: V Boden; C Colin; Jacques Barbet; JM Le Doussal; Mookambeswaran A Vijayalakshmi
Complementary approach for the determination of histidine in the metal-binding site of an anti-DTPA-indium monoclonal antibody.
Annals of the New York Academy of Sciences 1995;750():284-7.
1994: A Chetanneau; Jacques Barbet; P Peltier; JM Le Doussal; A Gruaz-Guyon; A M Bernard; Isabelle Resche; E Rouvier; Patrick Bourguet; M Delaage
Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate.
Nuclear medicine communications 1994;15(12):972-80.
1993: Jacques Barbet; JM Le Doussal; A Gruaz-Guyon; M Martin; Emmanuel Gautherot; M Delaage
Computer calculation of multiple binding equilibrium isotherms: application to the binding of bivalent ligands to antibodies interacting with cell surface Fc-receptors.
Journal of theoretical biology 1993;165(3):321-40.
1993: JM Le Doussal; A Chetanneau; A Gruaz-Guyon; M Martin; Emmanuel Gautherot; PAUL ANTOINE LEHUR; Jean-François Chatal; M Delaage; Jacques Barbet
Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993;34(10):1662-71.
1993: P Peltier; C Curtet; Jean-François Chatal; JM Le Doussal; G Daniel; G Aillet; A Gruaz-Guyon; Jacques Barbet; M Delaage
Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993;34(8):1267-73.
1992: JM Le Doussal; Jacques Barbet; M Delaage
Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1992;7():58-62.
1991: JM Le Doussal; Emmanuel Gautherot; M Martin; Jacques Barbet; M Delaage
Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(1):169-75.
1990: JM Le Doussal; A Gruaz-Guyon; M Martin; Emmanuel Gautherot; M Delaage; Jacques Barbet
Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice.
Cancer research 1990;50(11):3445-52.
1989: JM Le Doussal; M Martin; Emmanuel Gautherot; M Delaage; Jacques Barbet
In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1989;30(8):1358-66.